Molecular Diagnostics Market Research Report
The clinical laboratory, molecular diagnostics has become indispensable. This includes all methods and tests for the identification of a disease and comprehending the predisposition for a disease by analyzing DNA or RNA of an organism. The rapid advances in molecular diagnostics have significantly enabled basic research and results in practical diagnosis.
The clinical laboratory, molecular diagnostics has become indispensable. This includes all methods and tests for the identification of a disease and comprehending the predisposition for a disease by analyzing DNA or RNA of an organism. The rapid advances in molecular diagnostics have significantly enabled basic research and results in practical diagnosis.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
List of Figures<br />
2015-2017<br />
171. F. Hoffmann-La Roche AG: R&D Expenditure,<br />
2015-2017<br />
172. F. Hoffmann-La Roche AG: Revenue Forecast,<br />
2015-2020<br />
173. F. Hoffmann-La Roche AG: SWOT Analysis<br />
174. GUARDANT HEALTH, INC: Overall Product<br />
Portfolio<br />
175. GUARDANT HEALTH, INC: SWOT Analysis<br />
176. Illumina, Inc.: Overall Product Portfolio<br />
177. Illumina, Inc.: Overall Financials, 2015-2017<br />
178. Illumina, Inc.: Revenue (by Segment), 2015-2017<br />
179. Illumina, Inc.: Revenue (by Region), 2015-2017<br />
180. Illumina, Inc.: R&D Expenditure, 2015-2017<br />
181. Illumina, Inc.: Revenue Forecast, 2015-2020<br />
182. Illumina, Inc.: SWOT Analysis<br />
183. Invivoscribe Technologies, Inc.: Overall Product<br />
Portfolio<br />
184. Invivoscribe Technologies, Inc.: SWOT Analysis<br />
185. <strong>Molecular</strong>MD Corporation: Overall Product<br />
Portfolio<br />
186. <strong>Molecular</strong>MD Corporation: SWOT Analysis<br />
187. QIAGEN N.V.: Overall Product Portfolio<br />
188. QIAGEN N.V.: Overall Financials, 2015-2017<br />
189. QIAGEN N.V.: Revenue (by Segment), 2015-2017<br />
190. QIAGEN N.V.: Revenue (by Region), 2015-2017<br />
191. QIAGEN N.V.: R&D Expenditure, 2015-2017<br />
192. QIAGEN N.V.: Revenue Forecast, 2015-2020<br />
193. QIAGEN N.V.: SWOT Analysis<br />
194. Siemens Healthineers, Inc.: Overall Product<br />
Portfolio<br />
195. Siemens Healthineers, Inc.: Overall Financials,<br />
2016-2018<br />
196. Siemens Healthineers, Inc.: Revenue (by<br />
Segment), 2016-2018<br />
197. Siemens Healthineers, Inc.: Revenue (by Region),<br />
2016-2018<br />
198. Siemens Healthineers, Inc.: R&D Expenditure,<br />
2016-2018<br />
199. Siemens Healthineers, Inc.: Revenue Forecast,<br />
2015-2020<br />
200. Siemens Healthineers, Inc.: SWOT Analysis<br />
201. Thermo Fisher Scientific Inc.: Overall Product<br />
Portfolio<br />
202. Thermo Fisher Scientific Inc.: Overall Financials,<br />
2015-2017<br />
203. Thermo Fisher Scientific Inc.: Revenue (by<br />
Segment), 2015-2017<br />
204. Thermo Fisher Scientific Inc.: Revenue (by<br />
Region), 2015-2017<br />
205. Thermo Fisher Scientific Inc.: R&D Expenditure,<br />
2015-2017<br />
206. Thermo Fisher Scientific Inc.: Revenue Forecast,<br />
2015-2020<br />
207. Thermo Fisher Scientific Inc.: SWOT Analysis<br />
208. QuantuMDx Group Ltd.: Overall Product Portfolio<br />
(Available from FY2019)<br />
209. HTG <strong>Molecular</strong> <strong>Diagnostics</strong>, Inc.: Overall Product<br />
Portfolio<br />
210. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong><br />
Segmentation<br />
211. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> <strong>Research</strong><br />
Methodology<br />
212. Primary <strong>Research</strong><br />
213. Secondary <strong>Research</strong><br />
214. Data Triangulation<br />
215. Bottom-up Approach (Segment-wise Analysis)<br />
216. Top-down Approach (Segment-wise Analysis)<br />
217. Assumptions and Limitations<br />
218. Considered Factors for Data Prediction and<br />
Modeling<br />
sales@bisresearch.com | www.bisresearch.com
Change language